- Price
- 12,016.00p
- Market cap
- £186.37bn
- 1M
- +0.1%
- 3M
- -16.5%
- 1Y
- -0.1%
- P/E (trailing)
- —
- Dividend yield
- —
“Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to our full year 2024 guidance.”
EPS
Last 24 months of trading updates, one verdict per announcement (the headline profit measure first). Companies report these themselves and lean positive, so compare against peers: the same tag-based peer group as the Overview, counting peers with at least 2 updates and needing at least 3. Verdicts are machine-extracted; where the quoted wording clearly says otherwise, the wording is used.
“Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to our full year 2024 guidance.”
EPS
Last 24 months of trading updates, one verdict per announcement (the headline profit measure first). Companies report these themselves and lean positive, so compare against peers: the same tag-based peer group as the Overview, counting peers with at least 2 updates and needing at least 3. Verdicts are machine-extracted; where the quoted wording clearly says otherwise, the wording is used.